Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Aristides Maniatis

Pediatric Endocrinology Centennial, CO Medical Doctor

NPI 1316045701 CMS profile 150558

7336 S Yosemite St Ste 200, Centennial, CO 80112

Open in the dashboard

General payments

$654,935

904 records reported · program years 2019–2025

Research payments

$12,100

Paid to them · 16 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,395,078 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Aristides Maniatis of Centennial, CO is reported in the CMS Open Payments database as having received $654,935 across 904 general payments and $12,100 in research payments paid to them. Separately, studies naming them as principal investigator received $2,395,078 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $144,330 160
2025 Research $330 1
2024 General $141,985 155
2024 Research $4,760 3
2023 General $161,153 176
2023 Research $4,420 6
2022 General $118,578 214
2022 Research $1,320 4
2021 General $29,759 59
2021 Research $940 1
2020 General $19,797 31
2020 Research $330 1
2019 General $39,332 109

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aristides Maniatis
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Aristides Maniatis were reported at $144,330. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Aristides Maniatis Pediatric Endocrinology median Middle half National median
2019 $39,332 $196 $68–$845 $163
2020 $19,797 $124 $37–$722 $114
2021 $29,759 $134 $35–$691 $132
2022 $118,578 $177 $47–$726 $149
2023 $161,153 $236 $75–$887 $160
2024 $141,985 $259 $91–$979 $164
2025 $144,330 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ascendis Pharma, Inc. $243,413 320 payments
  2. Pfizer Inc. $132,919 89 payments
  3. Novo Nordisk Inc $115,222 156 payments
  4. BioMarin Pharmaceutical Inc. $67,248 94 payments
  5. Alexion Pharmaceuticals, Inc. $35,141 53 payments
  6. Novo Nordisk Health Care AG $29,402 24 payments
  7. Pfizer International LLC $15,476 6 payments
  8. Ferring Pharmaceuticals Inc. $3,959 18 payments
  9. Tandem Diabetes Care, Inc. $3,901 17 payments
  10. AbbVie, Inc. $1,739 43 payments
  11. Other $6,515 84 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $411,805 194 payments
  2. Consulting Fee $126,416 56 payments
  3. Travel and Lodging $87,062 253 payments
  4. Food and Beverage $17,048 375 payments
  5. Honoraria $11,972 3 payments
  6. Education $632 23 payments
Products named General payments · program years 2019–2025
  1. SKYTROFA $234,799 310 payments
  2. NGENLA $85,043 54 payments
  3. Sogroya $57,991 74 payments
  4. GENOTROPIN $52,510 41 payments
  5. Norditropin Growth Hormone $44,662 53 payments
  6. Norditropin Growth Hormone $15,933 18 payments
  7. VOXZOGO 1.2mg Achondroplasia $15,861 15 payments
  8. VOXZOGO 1.2MG Achondroplasia $13,898 20 payments
  9. STRENSIQ Rare Disease $8,695 19 payments
  10. Strensiq Endocrinology $8,364 14 payments
  11. Other $26,885 187 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $12,100 16 payments

Records

920 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record